These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 22266704)

  • 1. Impact of FDA drug risk communications on health care utilization and health behaviors: a systematic review.
    Dusetzina SB; Higashi AS; Dorsey ER; Conti R; Huskamp HA; Zhu S; Garfield CF; Alexander GC
    Med Care; 2012 Jun; 50(6):466-78. PubMed ID: 22266704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDA postmarketing safety labeling changes: What have we learned since 2010 about impacts on prescribing rates, drug utilization, and treatment outcomes.
    Rosenberg M; Sheehan S; Zhou E; Pinnow E; Burnell J; Romine M; Dal Pan G
    Pharmacoepidemiol Drug Saf; 2020 Sep; 29(9):1022-1029. PubMed ID: 32790031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia.
    Osborne SR; Alston LV; Bolton KA; Whelan J; Reeve E; Wong Shee A; Browne J; Walker T; Versace VL; Allender S; Nichols M; Backholer K; Goodwin N; Lewis S; Dalton H; Prael G; Curtin M; Brooks R; Verdon S; Crockett J; Hodgins G; Walsh S; Lyle DM; Thompson SC; Browne LJ; Knight S; Pit SW; Jones M; Gillam MH; Leach MJ; Gonzalez-Chica DA; Muyambi K; Eshetie T; Tran K; May E; Lieschke G; Parker V; Smith A; Hayes C; Dunlop AJ; Rajappa H; White R; Oakley P; Holliday S
    Med J Aust; 2020 Dec; 213 Suppl 11():S3-S32.e1. PubMed ID: 33314144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A descriptive analysis of medicines safety advisories issued by national medicines regulators in Australia, Canada, the United Kingdom and the United States - 2007 to 2016.
    Perry LT; Bhasale A; Fabbri A; Lexchin J; Puil L; Joarder M; Mintzes B
    Pharmacoepidemiol Drug Saf; 2020 Sep; 29(9):1054-1063. PubMed ID: 32696556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methodological approaches to evaluate the impact of FDA drug safety communications.
    Kesselheim AS; Campbell EG; Schneeweiss S; Rausch P; Lappin BM; Zhou EH; Seeger JD; Brownstein JS; Woloshin S; Schwartz LM; Toomey T; Dal Pan GJ; Avorn J
    Drug Saf; 2015 Jun; 38(6):565-75. PubMed ID: 25968811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of safety-related regulatory action on clinical practice: a systematic review.
    Piening S; Haaijer-Ruskamp FM; de Vries JT; van der Elst ME; de Graeff PA; Straus SM; Mol PG
    Drug Saf; 2012 May; 35(5):373-85. PubMed ID: 22480319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review of FDA Amendments Act Section 921 Experience in Posting Data-mining Results from the FAERS Database.
    Beninger P; Murray M
    Clin Ther; 2021 Feb; 43(2):380-395. PubMed ID: 33504449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDA drug safety communications: a narrative review and clinical considerations for older adults.
    Marcum ZA; Vande Griend JP; Linnebur SA
    Am J Geriatr Pharmacother; 2012 Aug; 10(4):264-71. PubMed ID: 22683398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time series analyses of the effect of FDA communications on use of prescription weight loss medications.
    Block JP; Choudhry NK; Carpenter DP; Fischer MA; Brennan TA; Tong AY; Matlin OS; Shrank WH
    Obesity (Silver Spring); 2014 Mar; 22(3):943-9. PubMed ID: 23929685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Effect of FDA Drug Safety Communications on Patterns of Tiotropium Dispensing: A U.S. Health Plan Claims Database Study.
    Major JM; Zhou EH; Ding Y; Ly T; Li J; Pinheiro SP; Seymour S
    J Manag Care Spec Pharm; 2018 Jul; 24(7):700-709. PubMed ID: 29952703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events.
    Starner CI; Schafer JA; Heaton AH; Gleason PP
    J Manag Care Pharm; 2008; 14(6):523-31. PubMed ID: 18693776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of publicity concerning pediatric suicidality data on physician practice patterns in the United States.
    Nemeroff CB; Kalali A; Keller MB; Charney DS; Lenderts SE; Cascade EF; Stephenson H; Schatzberg AF
    Arch Gen Psychiatry; 2007 Apr; 64(4):466-72. PubMed ID: 17404123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Public stewardship of private for-profit healthcare providers in low- and middle-income countries.
    Wiysonge CS; Abdullahi LH; Ndze VN; Hussey GD
    Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD009855. PubMed ID: 27510030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of Data Sources That Support US Food and Drug Administration Medical Devices Safety Communications.
    Tau N; Shepshelovich D
    JAMA Intern Med; 2020 Nov; 180(11):1420-1426. PubMed ID: 32986074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors influencing the implementation of medicine risk communications by healthcare professionals in clinical practice: A systematic review.
    Alharbi AB; Berrou I; Umaru N; Al Hamid A; Shebl NA
    Res Social Adm Pharm; 2023 Jan; 19(1):28-56. PubMed ID: 35989221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization and corroboration of safety signals identified from the US Food and Drug Administration Adverse Event Reporting System, 2008-19: cross sectional study.
    Dhodapkar MM; Shi X; Ramachandran R; Chen EM; Wallach JD; Ross JS
    BMJ; 2022 Oct; 379():e071752. PubMed ID: 36198428
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.